Trial · NCT00092677
Outcomes19
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events) | Entire follow-up (median = 4.35 years) | Intention-to-Treat | Participants | NUMBER |
| SECONDARY | Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of AVE (Aortic Valve Events) | Entire follow-up (median = 4.35 years) | Intention-to-Treat | Participants | NUMBER |
| SECONDARY | Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of ICE (Ischemic Cardiovascular Events) | Entire follow-up (median = 4.35 years) | Intention-to-Treat | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Cardiovascular Death | Entire follow-up (median = 4.35 years) | Intention-to-Treat | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Aortic Valve Replacement (AVR) | Entire follow-up (median = 4.35 years) | Intention-to-Treat | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Congestive Heart Failure (CHF) Due to Progression of Aortic Stenosis (AS) | Entire follow-up (median = 4.35 years) | Intention-to-Treat | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Nonfatal Myocardial Infarction (MI) | Entire follow-up (median = 4.35 years) | Intention-to-Treat | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Coronary Artery Bypass Grafting (CABG) | Entire follow-up (median = 4.35 years) | Intention-to-Treat | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Percutaneous Coronary Intervention (PCI) | Entire follow-up (median = 4.35 years) | Intention-to-Treat | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Hospitalization for Unstable Angina | Entire follow-up (median = 4.35 years) | Intention-to-Treat | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Nonhemorrhagic Stroke | Entire follow-up (median = 4.35 years) | Intention-to-Treat | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Death (Any Cause) | Entire follow-up (median = 4.35 years) | Intention-to-Treat | Participants | NUMBER |
| POST_HOC | Death Due to Cancer | Entire follow-up (median = 4.35 years) | Intention-to-Treat | Participants | NUMBER |
| POST_HOC | Incident Cancer | Entire follow-up (median = 4.35 years) | One patient from the 944 patients randomized to ezetimibe/simvastatin 10/40 mg did not receive study medication and was not included. | Participants | NUMBER |
| SECONDARY | Change From Baseline in Peak Transaortic Jet Velocity | Baseline to End of follow-up (median = 4.35 years) or pre-aortic valve replacement | Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication. 180 patients were excluded from peak transaortic jet velocity due to missing measurements. | m/sec | MEAN |
| OTHER_PRE_SPECIFIED | Percent Change in Time Weighted Average Total Cholesterol From Baseline to End of Follow-up | Baseline to End of follow-up (median = 4.35 years) | Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication. | Percent Change | MEAN |
| OTHER_PRE_SPECIFIED | Percent Change in Time Weighted Average Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to End of Follow-up | Baseline to End of follow-up (median = 4.35 years) | Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication. | Percent Change | MEAN |
| OTHER_PRE_SPECIFIED | Percent Change in Time Weighted Average High-density Lipoprotein Cholesterol (HDL-C) From Baseline to End of Follow-up | Baseline to End of follow-up (median = 4.35 years) | Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication. | Percent change | MEAN |
| OTHER_PRE_SPECIFIED | Percent Change in Time Weighted Average Triglycerides From Baseline to End of Follow-up | Baseline to End of follow-up (median = 4.35 years) | Full Analysis Set: All patients who were randomized, took at least one dose of blinded study therapy and had a baseline and at least one post-randomization assessment without regard to protocol violations or compliance with study medication. | Percent Change | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00092677/outcomes